907 related articles for article (PubMed ID: 18230901)
1. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
4. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
5. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Seckl JR; Morton NM; Chapman KE; Walker BR
Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
[TBL] [Abstract][Full Text] [Related]
7. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.
Paterson JM; Morton NM; Fievet C; Kenyon CJ; Holmes MC; Staels B; Seckl JR; Mullins JJ
Proc Natl Acad Sci U S A; 2004 May; 101(18):7088-93. PubMed ID: 15118095
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
11. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
12. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
13. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
15. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
16. Dietary manipulation reveals an unexpected inverse relationship between fat mass and adipose 11β-hydroxysteroid dehydrogenase type 1.
Man TY; Michailidou Z; Gokcel A; Ramage L; Chapman KE; Kenyon CJ; Seckl JR; Morton NM
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1076-84. PubMed ID: 21406612
[TBL] [Abstract][Full Text] [Related]
17. Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.
Paterson JM; Holmes MC; Kenyon CJ; Carter R; Mullins JJ; Seckl JR
Endocrinology; 2007 Mar; 148(3):961-6. PubMed ID: 17170103
[TBL] [Abstract][Full Text] [Related]
18. 11β-HSD1 contributes to age-related metabolic decline in male mice.
Morgan SA; Gathercole LL; Hassan-Smith ZK; Tomlinson J; Stewart PM; Lavery GG
J Endocrinol; 2022 Dec; 255(3):117-129. PubMed ID: 36205523
[TBL] [Abstract][Full Text] [Related]
19. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
20. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]